Research, news, publications, data and infographics on myriad topics related to the health, medical and pharmaceutical fields.
Canada
- Tweets 1,357
- Following 830
- Followers 760
- Likes 153
Pinned Tweet
The Trillion Dollar Potential of Ozempic
Unintended side effect to bona fide blockbuster drug, Novo Nordisk's magnum opus, upon the rising crest of obesity, is charting a path to become the highest-selling drug worldwide in the next 5 years.
Read our article for free below.
ALT The Trillion Dollar Potential of Ozempic
1
1
1
4,703
Antropy Health Insights retweeted
An experimental cancer vaccine kept melanoma from coming back. It’s the first successful late-stage mRNA study validating decades of custom-treatment research on.wsj.com/4qy7Ule
77
677
2,811
786,186
Antropy Health Insights retweeted
We are entering into a new strategic partnership with Amazon Web Services (@awscloud) to accelerate drug discovery through AI.
Learn more in the press release here: novonordisk.com/news-and-med…
19
44
505
34,359
Ozempic has the staggering potential to reshape the healthcare landscape, lessen the global chronic disease impact, alleviate the costs on the healthcare system, improve quality of life, while also turbocharging workforce productivity and global GDP by trillions of dollars.
The Trillion Dollar Potential of Ozempic
Unintended side effect to bona fide blockbuster drug, Novo Nordisk's magnum opus, upon the rising crest of obesity, is charting a path to become the highest-selling drug worldwide in the next 5 years.
Read our article for free below.
ALT The Trillion Dollar Potential of Ozempic
190
In the midst of a paradigm shift in the treatment of obesity through a more weight-centric approach, would it be a stretch to suggest that Ozempic could help humans age with fewer chronic diseases?
The obesity landscape in 2030: a quick glance at the projections.
As we stand on the cusp of the emergence of a new therapeutic armament, obesity is the eldorado of the next decade’s healthcare, akin to an untapped titanic oil field.
Details below.
ALT The obesity landscape in 2030
282
Antropy Health Insights retweeted
Canada becomes the first G7 country to approve a generic version of semaglutide
ow.ly/QFt8106xPgO
14
78
380
208,291
Our analysis uses AI to compute a pipeline rating for each pharma on a scale of 0.0 to 10.0, and combines the results from ChatGPT, Gemini, Claude and Grok. A 10.0 rating represents a highly diversified, high-value pipeline with considerable breakthrough potential.
(2/2)
#AI
1
281
FDA approves Wegovy oral medication for weight loss.
According to Novo Nordisk's representatives, the Wegovy pills are expected to be available within weeks. The starting dose will be available for $149 per month.
$NVO is up 8% today.
Novo Nordisk's oral Wegovy pill (semaglutide 25 mg) is nearing an FDA decision in Q4 2025.
If approved, the impact will be seismic, as it will become the first oral GLP-1 available for weight loss in the US.
$NVO #Wegovy #GLP1 #Pharma
ALT Novo Nordisk
321
Retatrutide, an experimental drug currently in Phase 3 clinical trials, is nicknamed the Godzilla of weight-loss jabs because of its potential superior efficacy.
Developed by Eli Lilly, retatrutide is a triple hormone receptor agonist (GLP-1, GIP and glucagon).
$LLY #GLP1
ALT Weight-loss drugs chart
1
1
657
Antropy Health Insights retweeted
By 2030, Eli Lilly will become the top seller of prescription drugs worldwide, ahead of Novo Nordisk.
Projections for 2030
1. $LLY : $113B
2. $NVO : $84B
3. $ABBV : $75B
4. $JNJ : $68B
5. $ROG.SW : $66B
6. $SNY : $65B
7. $AZN : $64B
8. $MRK : $60B
9. $NVS : $58B
10. $PFE : $50B
1
1
277
Merck $MRK has a new groundbreaking cholesterol pill: enlicitide, a PCSK9 inhibitor.
- Lowered LDL-C levels by 60% compared to placebo
- Efficacy comparable to injectables, including Amgen’s Repatha and Regeneron’s Praluent
- FDA application planned for early 2026
#Pharma
Today at #AHA25, we shared first-time Phase 3 results of our investigational oral macrocyclic peptide. Learn more: merck.us/47tZof8
285
The Trillion Dollar Potential of Ozempic
Unintended side effect to bona fide blockbuster drug, Novo Nordisk's magnum opus, upon the rising crest of obesity, is charting a path to become the highest-selling drug worldwide in the next 5 years.
Read our article for free below.
ALT The Trillion Dollar Potential of Ozempic
75
Antropy Health Insights retweeted
Novo Nordisk is extremely well positioned for the future, with 3 products in the projected top 10 best-selling drugs worldwide in 2030, a triumvirate of blockbusters that will cement the company’s standing as a Big Pharma powerhouse.
Ozempic (#1)
Cagrisema (#4)
Wegovy (#7)
$NVO
The obesity landscape in 2030: a quick glance at the projections.
As we stand on the cusp of the emergence of a new therapeutic armament, obesity is the eldorado of the next decade’s healthcare, akin to an untapped titanic oil field.
Details below.
ALT The obesity landscape in 2030
1
1
2
550